GlassScriptPhysician profile
Cheryl M Gerke
NPI 1114115714
$1,166.28
in general payments reported to CMS, 2019-2025
14 companies · $136 in 2025
The $136 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $451 · 2022: $238 · 2023: $96.94 · 2024: $244 · 2025: $136.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $477.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $477.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $334.31 | 2021-2024 | Azstarys |
| Supernus Pharmaceuticals, INC. | $166.96 | 2024-2025 | Qelbree |
| Tris Pharma INC | $160.49 | 2021-2022 | |
| Pfizer INC. | $100.43 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $83.48 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $76.96 | 2021-2024 | Gardasil, Vaxelis, Gardasil 9 |
| Neos Therapeutics, LP | $42.50 | 2021 | |
| Ironshore Pharmaceuticals INC. | $39.01 | 2024 | |
| Cranial Technologies, INC | $37.56 | 2024 | Doc Band |
| Phadia US INC. | $33.66 | 2021-2025 | Immunocap |
| Sanofi Pasteur INC. | $33.58 | 2021-2023 | |
| Verrica Pharmaceuticals INC. | $23.51 | 2025 | Ycanth |
| Alk-Abello, INC | $18.62 | 2025 | Neffy, Grastek, Odactra |
| Glaxosmithkline, LLC. | $15.21 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cheryl Gerke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.